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http://www.biomedcentral.com/1471-2407/13/233RESEARCH ARTICLE Open AccessCisplatin-induced caspase activation mediates
PTEN cleavage in ovarian cancer cells: a potential
mechanism of chemoresistance
Mohan Singh1†, Parvesh Chaudhry1†, Francois Fabi1 and Eric Asselin1,2*Abstract
Background: The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor
protein is a central negative regulator of the PI3K/AKT signaling cascade and suppresses cell survival as well
as cell proliferation. PTEN is found to be either inactivated or mutated in various human malignancies. In the
present study, we have investigated the regulation of PTEN during cisplatin induced apoptosis in A2780, A270-CP
(cisplatin resistant), OVCAR-3 and SKOV3 ovarian cancer cell lines.
Methods: Cells were treated with 10μM of cisplatin for 24h. Transcript and protein levels were analysed by
quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and western blotting, respectively.
Immunofluorescence microscopy was used to assess the intracellular localization of PTEN. Proteasome inhibitor and
various caspases inhibitors were used to find the mechanism of PTEN degradation.
Results: PTEN protein levels were found to be decreased significantly in A2780 cells; however, there was no
change in PTEN protein levels in A2780-CP, OVCAR-3 and SKOV3 cells with cisplatin treatment. The decrease in
PTEN protein was accompanied with an increase in the levels of AKT phosphorylation (pAKT) in A2780 cells and a
decrease of BCL-2. Cisplatin treatment induced the activation/cleavage of caspase-3, -6, -7, -8, -9 in all cell lines
tested in this study except the resistant variant A2780-CP cells. In A2780 cells, restoration of PTEN levels was
achieved upon pre-treatment with Z-DEVD-FMK (broad range caspases inhibitor) and not with MG132 (proteasome
inhibitor) and by overexpression of BCL-2, suggesting that caspases and BCL-2 are involved in the decrease of PTEN
protein levels in A2780 cells.
Conclusion: The decrease in pro-apoptotic PTEN protein levels and increase in survival factor pAKT in A2780
ovarian cancer cells suggest that cisplatin treatment could further exacerbate drug resistance in A2780 ovarian
cancer cells.
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The tumor suppressor phosphatase and tensin homolog
(PTEN) is negative regulator of the PI3K/AKT pathway
[1]. Decrease in PTEN levels could lead to increase in
phosphorylation and activation of AKT, which further
promotes cell survival and proliferation [2]. Phosphatase* Correspondence: eric.asselin@uqtr.ca
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reproduction in any medium, provided the oractivity of PTEN is known to be responsible for the
regulation of apoptosis, proliferation and cell migration
[3,4]. Epigenetic and genetic changes in PTEN are the
crucial factors for PTEN activity and PTEN is mostly
found to be deleted or mutated in various human can-
cers [5]. Ovarian cancer is one of the leading gynecologic
malignancy. After surgical intervention for ovarian can-
cer, cisplatin based chemotherapy is the mainstay for
treatment. Major challenge to fight ovarian cancer is the
development of chemoresistance. In spite of the exten-
sive research in the field of cancer, certain mechanism of
chemoresistance remained unresolved.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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act by inducing apoptosis. During apoptosis, a structur-
ally related group of cysteine proteases known as
caspases mediate protein cleavage [6,7]. Caspases can
be classified into two groups, more precisely initiator
and effector caspases. Initiator caspases group includes
caspase-6, -8, -9, and −10; they are responsible in initiat-
ing a proteolytic cascade by activating the pro-caspases
to amplify the death signal. The second group, consists
of caspase-2, -3, and −7, are known as effector caspases;
they are activated by the initiator caspases [8]. A pleth-
ora of caspase substrates have been identified till date
and the list is expanding fast [9].
Previous studies suggest that PTEN can be regulated
at the transcriptional and post-translational levels
through multiple molecular pathways [10-12]. Recently,
it has been found that microRNAs can also target PTEN,
regulate AKT signaling pathway and induce cisplatin
chemoresistance in ovarian cancer cells [13]. Treatment
with cisplatin activates the caspases cascades in the cells,
which further leads to the induction of apoptosis
[14-16]. Recent study from our lab determined that cis-
platin induced activation of caspase-3 can cleave tumor
suppressor Par-4 protein, associated with selective killing
of cancer cells, suggesting that activated caspases could
target cellular proteins involved in tumor suppression
[9]. It has been shown that caspase-3 can cleave PTEN
in HEK293 cellular extracts and furthermore demon-
strated that C-terminal cleavage by caspase-3 is nega-
tively regulated by phosphorylation of Ser370 and/or
Ser385 [10]. Based on these studies, we hypothesize that
cisplatin induced caspase activation could target PTEN
in ovarian cancer cells. The outcomes of the present study
indicate that cisplatin mediated caspases activation leads
to the cleavage of PTEN which results in AKT phosphor-
ylation in ovarian cancer cells suggesting that cisplatin
based chemotherapy could induce chemoresistance by
targeting PTEN in ovarian cancer cells.
Results
Cisplatin treatment decreases PTEN protein levels
A2780 cells were treated with 10μM cisplatin (based on pre-
vious studies from lab) and the results revealed that PTEN
protein levels were markedly decreased after 24 h cisplatin
treatment (Figure 1A). The time interval for the treatment
was based on the time course study (Additional file 1:
Figure S1). This decrease in PTEN protein levels could be a
result of decreased transcript levels; therefore, we evaluated
PTEN mRNA levels. The results of real-time quantitative
PCR demonstrated that PTEN transcript levels remain un-
changed following cisplatin treatment (Figure 1B). We were
further interested to know whether cisplatin treatment also
effects the intracellular localization of PTEN (Figure 1C&D).
Immunofluorescence analysis confirmed reduced levelsof PTEN proteins after cisplatin treatment (Figure 1D).
Further, nuclear PTEN levels were found to be de-
creased in cisplatin treated A2780 cells with membrane
localization as seen by yellow color development due to
red labeled actin and green labeled PTEN in merged
picture (Figure 1D).
Additionally, we also tested various other ovarian cancer
cell lines for PTEN levels following cisplatin treatment.
The results showed that there was no change in PTEN
protein levels in A2780-CP (cisplatin resistant), SKOV3
and OVCAR-3 ovarian cancer cells (Figure 2A-C).
Cisplatin treatment promotes phosphorylation of AKT
PTEN is known as a negative regulator of AKT phos-
phorylation. The phosphorylation of AKT was analyzed
using western blotting in various cell lines. Significant
levels of phosphorylated form of AKT were observed in
case of A2780 cells (Figure 3A). However phosphory-
lation level of AKT remained unchanged in A2780-CP,
OVCAR-3 and SKOV3 cells (Figure 3B-C). This result
indicates that in spite of inducing cell death, cisplatin
could promote cell survival and proliferation in ovarian
cancer cells.
Proteasomal degradation of PTEN in presence of cisplatin
To ascertain, whether cisplatin mediated decrease of
PTEN protein is due to ubiquitin-proteasome pathway,
we used MG132, a proteasome inhibitor during present
study. A2780 cells were pretreated with MG132 at two
different concentrations (1μM & 2μM) for 1h followed
by the treatment of cisplatin 10μM for 24h. Immuno-
blotting revealed that pretreatment with MG132 could
not restore PTEN protein levels (Figure 4). These results
indicate that cisplatin mediated decrease in PTEN pro-
tein levels are not due to induction of proteasomal deg-
radation of PTEN but could be due to some other post-
translational mechanism.
Caspases activation and levels of anti-apoptotic molecules
Caspases are known to be activated during apoptosis in-
duction. In order to understand the differential activa-
tion of caspases between the individual cell lines, various
caspases were studied. Western blotting results revealed
that treatment with cisplatin induced the activation of
initiator (caspase-6; caspase-8; caspase-9) and effector
caspases (caspase-3; caspase-7) in A2780, SKOV3 and
OVCAR-3 cells (Figure 5A, C-D). However, none of the
caspases were found to be active in A2780-CP (cisplatin
resistant cells) as depicted in Figure 5B.
Inhibitors of apoptosis (IAPs) can directly or indirectly
inhibit caspases or pro-caspases [17,18]. For example, XIAP,
cIAP1 and cIAP2 can prevent the proteolytic processing of
pro-caspases −3, -6 and −7 by blocking the cytochrome



























































Figure 2 PTEN protein levels in cisplatin treated resistant and less sensitive ovarian cancer cells. (A) A2780-CP cells (B) OVCAR-3 cells
(C) SKOV3 cells were treated with cisplatin (10μM) for 24 hrs. Protein levels were analyzed using western blotting. GAPDH was used as a



















































Figure 1 Post-translational regulation of PTEN by cisplatin treatment. (A) PTEN protein levels in A2780 cells after 24 hrs cisplatin treatment.
GAPDH was used as loading control. Graphs show densitometric analysis of three independent experiments. * p < 0.05 compared to vehicle treated
cells. (B) Real-time quantitative PCR analysis for PTEN relative mRNA levels in A2780 cells after 24 hrs of cisplatin treatment. GAPDH was used as internal
control. (C & D) A2780 cells were grown on glass coverslips and treated with cisplatin for 24hrs. Following treatment, cells were fixed using 4%
paraformaldehyde and immunofluorescence was performed using PTEN (Green) antibody. Nuclei were counterstained with Hoechst 33258 (blue)
and rodamine phalloidin (red) was used to stain actin cytoskeleton and to visualize the shape and cellular integrity. Magnification: 63 × .
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Figure 3 Cisplatin treatment in A2780 ovarian cancer cells increased phosphorylation of AKT in A2780 cells. (A) A2780 cells (B) A2780-CP
cells (C) OVCAR-3 cells (D) SKOV3 cells were treated with cisplatin (10μM) for 24 hrs. pAKT protein levels were analyzed using western blotting.
GAPDH was used as a loading control. * p < 0.05 compared to vehicle treated cells.
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caspase-3 and −7. Furthermore, IAPs can also inhibit
caspase-3 directly and thus blocking downstream apoptotic
events. We have analyzed the levels of various inhibitors
of apoptosis to find out the difference among A2780
and other cell lines tested in this study. Decrease in the pro-
tein levels of BCL-2, cIAP-1, survivin and XIAP were ob-
served upon cisplatin treatment in A2780 cells, showing
sensitivity towards cisplatin treatment (Figure 6A). On the
other hand, no changes were observed in the levels of
various IAPs in A2780-CP cells, owing their resistance
towards cisplatin treatment (Figure 6B). Among all the
IAPs tested, only survivin protein levels in case of SKOV3
(Figure 6C) andcIAP-1 protein levels in case of OVCAR-3
cells were found to be decreased (Figure 6D) suggesting
that Bcl-2 protein levels could regulate the caspase activa-
tion in A2780 cells. In order to confirm this, we have
overexpressed Bcl-2 in the A2780 cells (Figure 7).- +      - +      -
- - - - MG-
- - - -
+ +




Figure 4 Cisplatin treatment of ovarian cancer cells does not
induce proteasomal degradation of PTEN. A2780 cells were
pre-treated with 1 μM and 2 μM of proteasome inhibitor (MG-132)
for 1 hr followed by cisplatin (10μM) treatment for 24 hrs. Protein
levels were analyzed using western blotting. GAPDH was used
as a loading control.Interestingly, overexpression of Bcl-2 blocked cisplatin me-
diated decrease in PTEN protein level. Overexpression of
Bcl-2 could resist cisplatin induced apoptosis by blocking
the release of cytochrome c from mitochondria thereby
inhibiting the activation of downstream caspases which
could be involved in the degradation/cleavage of PTEN.
Role of caspases in PTEN protein degradation
As caspase activation leads to the proteolytic cleavage of
various substrates [9] and the results in Figure 5 also
demonstrate that various caspases were found to be acti-
vated in A2780 cell line, therefore, we determined
whether caspase activation could mediate the decrease
in PTEN protein levels using caspases inhibitors.
Caspases inhibitors act by binding to the active site of
caspases either in a reversible or irreversible manner but
they do not affect the protein levels of caspases. A2780
cells were pretreated with 20μM of broad range caspase
inhibitor (Z-DEVD-FMK) and subsequently treated with
10μM of cisplatin for an additional 24h. Pre-treatment
with broad range caspases inhibitor significantly restored
PTEN protein levels in cisplatin treated A2780 cells
(Figure 8A). This result indicates the potential role of
caspases in PTEN degradation upon cisplatin treatment.
Furthermore, to determine the involvement of specific
caspase in PTEN protein degradation/cleavage, we
pretreated the A2780 cells with 40μM of caspase-3 inhibi-
tor for 1h followed by cisplatin treatment (Figure 8B). Pre-
treatment with caspase-3 inhibitor restored the PTEN
protein levels in A2780 cells. Similar results were ob-
served, when A2780 cells were pretreated with specific in-
hibitor of caspase-6 and caspase-8 (Figure 8C-D).
Collectively, these results suggest that PTEN is a novel
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Figure 5 Cisplatin treatment in ovarian cancer cells activates caspase family members. Caspases are active in all the cell line tested except
cisplatin resistant cell line (A2780-CP). Activated forms of caspases are measured using Western blot assay. GAPDH was used as a loading control.
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platin treatment could be the key factor involved in devel-
oping chemoresistance in ovarian cancer cells.
Discussion
PTEN is a putative tumor suppressor protein and a key
regulatory molecule of AKT signaling pathway. PTEN pos-
sesses lipid phosphatase activity against 3-phosphoinostides
opposing PI3K, finally negatively regulating AKT phosphor-
ylation [19]. In the present study, we demonstrate the role
of caspases in the regulation of PTEN levels during cis-
platin induced apoptosis. In this study we have found that
cisplatin induced activation of multiple caspases leads to
proteolytic cleavage of PTEN in A2780 cells. Cisplatin treat-
ment induced PTEN degradation in A2780 cells is indica-
tive of post-translational regulation. The activation of AKT
by PIP3 production initiates multiple signaling pathways
by phosphorylating various downstream targets and by
inactivating the inhibitors of cell cycle, protein synthesis
glycolysis and angiogenesis. Summarily, it can be said that
AKT paves the way for oncogenesis [20,21]. The decrease
in PTEN levels leads to the activated form of AKT whichcould further promotes cellular proliferation and survival in
A2780 cells. We have not observed any change in AKT
phosphorylation in A2780-CP, OVCAR-3 and SKOV3 cells
which could be due the fact that there was no change in
the PTEN levels, suggesting that there is a direct relation-
ship between these two proteins in ovarian cancer cells. In
addition, cisplatin prevents the nuclear localization of
PTEN in A2780 cells which is in accordance with our pre-
vious study. In the latter study XIAP knockdown prevents
nuclear localization of PTEN, we have also observed that
XIAP levels are decreased upon cisplatin treatment which
could prevent the nuclear localization of PTEN in the
present study. Proteins can undergo proteasomal degrad-
ation under external stimuli [22,23]. To validate this hy-
pothesis, we pretreated the cells with MG132, a
proteasomal inhibitor and subsequently treated with cis-
platin. However there was no restoration of PTEN levels in
presence of MG132 and cisplatin (Figure 4; Lane 4). Low
levels of PTEN was also observed in the only MG132
treated cells because MG132 itself is an apoptotic agent,
which further activates caspase-3 (Figure 4; Lane 3) and this
activation of caspase −3 could lead to a decrease in the level
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Figure 6 Levels of Inhibitors of apoptosis (IAPs) in cisplatin treated ovarian cancer cells. (A) Treatment of cisplatin in A2780 cells
decreased BCl-2, XIAP, cIAP1 and survivin protein levels. (B) No change in IAPs was observed in A2780-CP cells. (C) Decreased levels of survivin in
SKOV3 cell lines. (D) Decrease in cIAP1 level was observed in case of OVCAR cells. GAPDH was used as loading control.
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accordance with previously published report [12]. Collect-
ively the results from the present study suggest that PTEN
does not undergo proteasomal degradation in the presence
of cisplatin in A2780 cells.
Cisplatin treatment can initiate both the intrinsic and
extrinsic pathways of caspases activation [24]. The acti-
vation of various initiator and effector caspases in
A2780, OVCAR-3 and SKOV3 cells except A2780-CP
cells is indicative of the activation of both apoptotic
pathways. However, no particular caspases activation dif-
ference was observed among individual cell lines. We
could not find out the involvement of any particular
caspase in the PTEN degradation from these results. Cell
fate is determined by a delicate balance between pro-
apoptotic and anti-apoptotic factors [25]. XIAP can
inhibit caspase-3 and caspase-7 by directly binding to
them [26]. Previous studies have shown that IAPs can
inhibit caspases directly or indirectly [17,18] and
we have shown that XIAP overexpression can induce
chemoresistance in A2780 cells, while XIAP antisensedownregulation leaded to increased sensitivity in A2780-
CP cells [27]. All the IAPs (BCL-2, cIAP-1, survivin and
XIAP) studied in A2780 cells were found be decreased
upon cisplatin treatment. However, decreased survivin
levels were observed in SKOV3 cells and decreased in
cIAP-1 protein levels were seen in OVCAR-3 cells in the
presence of cisplatin. As PTEN levels remained stable in
SKOV3 and OVCAR-3 cells, we could rule out the role
of survivin and c-IAP-1 in caspase mediated PTEN deg-
radation. However, we have observed low endogenous
level of BCL-2 in A2780 cells and furthermore BCL-2
level was almost diminished after cisplatin treatment.
Decreased levels of BCL-2 could be the reason for
higher activation of caspases in A2780 cells owing
greater sensitivity than other cell line tested and cleavage
of PTEN by activated caspases. Finally, pretreatment
with specific caspases inhibitors restored PTEN levels in
cisplatin treated cells suggesting the involvement of
more than one caspase in PTEN degradation. This result
further suggests that PTEN protein sequence contains
multiple cleavage sites.
- +             -





























Figure 7 Overexpression of BCL-2 prevents cisplatin mediated
PTEN degradation in A2780 cells. A2780 cells were transfected
with 2ug Bcl-2 plasmid or empty vector. After 48h of transfection,
cells were treated with cisplatin and proteins were analyses by
western blotting and GAPDH was used as loading control. Graphs
show densitometric analysis of PTEN and BCL-2 in various groups.
* p < 0.05 compared to vehicle treated cells, # p < 0.05 compared to
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Figure 8 Pre-treatment with caspase inhibitor restores PTEN levels. (A
(Z-DEVD-FMK) for 1hr at concentration of 20μM followed by 10μM cisplatin
inhibitor (40 μM) for 1hr followed by 10μM cisplatin treatment for 24hrs. (C
followed by 10μM cisplatin treatment for 24hrs. (D) A2780 cells were pre-tr
cisplatin treatment for 24hrs. Protein levels were analyzed using western bl
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This study provides the first evidence that PTEN protein
can be targeted during cisplatin induced caspases activa-
tion in A2780 cells. Caspases-mediated decrease in
PTEN levels further affect AKT signaling pathway, which
plays an important role in regulating chemosensitivity in
ovarian cancer. The present study could provide new in-
sights to understand cisplatin-induced chemoresistance
in ovarian cancers and could explain underlying mecha-
nisms involved in PTEN regulation.
Methods
Cell culture
Human ovarian cancer cell lines A2780, A2780-CP (cis-
platin resistant), cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM/F12) supplemented with
2% BGS (Bovine Growth Serum) (Thrmo Scientific,
Rockford, IL) and 50μg/ml of gentamicin. OVCAR-3
cells were cultured in RPMI-1640 supplemented with
10% FBS (Fetal Bovine Serum) (Thrmo Scientific, Rock-
ford, IL) and 50μg/ml of gentamicin. SKOV3 cells were
cultured in Mc-Coy’s medium supplemented with 10%
FBS and 50μg/ml of gentamicin.
Reagents and antibodies
AKT total (9272), phospho-AKT (9271), BCL-2 (2872),
C-IAP1 (7065), cleaved-caspase-3 (9661), cleaved-caspase-6
(9761), cleaved-caspase-7 (9491), cleaved-caspase-8 (9748),
cleaved-caspase-9 (9505), PTEN (9559), phospho-PTEN
(9554), Survivin (3879) and XIAP (2042) antibodies were
purchased from Cell Signaling (Danvers, MA). Anti-
GAPDH(HRP) antibody (9385) was procured from Abcam
Inc. (Cambridge, MA) Cisplatin, Proteasomal inhibitor
(MG132), and Hoechst 33248 were obtained from
Sigma-Aldrich (St. Louis, MO). Broad range Caspase-3Cl-Caspase-8
GAPDH
- +       -
- - -8 Inhibitor
PTEN
- +       -
- -
+ + Caspase






) A2780 cells were pre-treated with broad range caspase inhibitor
treatment for 24hrs. (B) A2780 cells were pre-treated with caspase-3
) A2780 cells were pre-treated with caspase-6 inhibitor (40 μM) for 1hr
eated with caspase-8 inhibitor (40 μM) for 1hr followed by 10μM
ot analysis. GAPDH was used as a loading control.
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VII (219012), Caspase-6 Inhibitor I [Z-VEID-FMK
(218757)] and Caspase-8 Inhibitor I [IETD (218773)] were
obtained from Calbiochem (San Diego, CA).
Western blot analysis
Following different treatments cells were washed with PBS
and submitted to lysis in cold radioimmune precipitation
assay (RIPA) lysis buffer containing protease inhibitors
(Complete™ from Roche Applied Science) followed by
three freeze-thaw cycles. Equal amounts of cell lysates (as
determined using Bio-Rad DC protein assay) were sepa-
rated onto 10%-15% polyacrylamide gels and then trans-
ferred onto nitrocellulose membranes (Bio-Rad, Hercules,
CA). The membranes were blocked with 5% milk in PBS
containing 0.05% Tween 20 for 1h at room temperature,
overnight incubated with primary antibody, washed in PBS
with 0.05% Tween 20, and probed with horseradish
peroxidase-conjugated secondary antibody (Bio-Rad,
Hercules, CA). Protein detection was performed using
SuperSignal West Femto™ substrate (Thremo Scientific,
Rockford, IL), as described by the manufacturer.
RNA isolation and quantitative-RT-PCR (Reverse
Transcription-Polymerase Chain Reaction)
Total RNA was isolated from cells using Purelink™ RNA
Mini Kit (Cat no. 12183020 Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions. First strand
cDNA was synthesized from 1μg of RNA using qScript™
cDNA Supemix (Quanta Biosciences Inc. Gaithersburg,
MD). Primers used for amplification were as follows: (i)
PTEN forward 5’-ACCCCTTCATTGACCTCAACTA-3’
and reverse 5’-TCTCGCTCCTGGAAGATGGTGA-3’ (ii)
GAPDH forward 5’-TGAAGGCGTATACAGGAACAAT-
3’ and reverse 5’-CGGTGTCATAATGTCTTTCAGC-3’.
PCRs were conducted in LightCycler (Roche). Data were
analyzed by using LightCycler Software Version 4.1.
Transient transfection using BCL-2 plasmid
BCL-2 (pcDNA3 BCL-2) and empty (pcDNA3) plasmids
were purchased from Addgene. One day before transfec-
tion, cells were plated at 3×105/well to achieve a confluency
of ~70% .Next day cells were transfected with 2μg of ex-
pression vector using Fugene6 (Roche, Indianapolis, IN)
according to manufacturer’s instructions. Cells were incu-
bated for 48h at 37°C, and the medium was replenished
with fresh medium containing cisplatin (10μM). The plates
were incubated for an additional 24h before the cells were
collected.
Confocal immunofluorescent analysis
Cells were grown on to sterile coverslips in 6 well plates.
After cisplatin treatment, cells were fixed with 4% para-
formaldehyde for 10min, and washed twice with PBS for5min. Cells were permeabilized using permeabilizing so-
lution (0.1% Triton, 0.1% sodium citrate) for 10min
followed by incubation with Dako blocking serum for
1h. After blocking, cells were incubated with the PTEN
primary antibodies or isotypic control antibodies. Both
were diluted at a ratio of 1/100 for 1h. After washing with
PBS, cells were incubated with fluorescent tag conjugated
secondary antibodies (as mentioned in figure legends) for
30min in dark. Cells were counter stained with Hoechst
33248 (0.25μg/ml) for 5min, slides were mounted using
slowfade gold anti-fading reagent (Invitrogen) and viewed
under Carl Zeiss Axio observerZ1 microscope.
Statistical analysis
All the experiments were repeated three times. Data were
subjected to one-way ANOVA (PRISM software version
4.0; GraphPad, San Diego, CA) followed by Newman-
Keuls test to determine the differences between the experi-
mental groups. Differences were considered significant at
the level of P < 0.05.
Additional file
Additional file 1: Figure S1. Cisplatin treatment decreases PTEN
protein levels in a time dependant manner. Cells were treated with
cisplatin (10 μM) for increasing time intervals (2, 4, 8, 16 and 24h). Total
proteins were then extracted and analysed by Western blot using a PTEN
antibody. GAPDH was used as the loading control. Densitometric analysis
was performed to quantify protein levels. (PPTX 69 kb)
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